Altimmune presents data at EASL International Liver Congress 2024

Altimmune presented new data on the potential anti-inflammatory and anti-fibrotic properties of pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis, MASH, at the EASL International Liver Congress 2024 in Milan, Italy. The data presented are summarized below: Pemvidutide treatment is associated with improvement in non-invasive tests indicating greater likelihood of histologic response in subjects with metabolic dysfunction-associated steatotic liver disease: a 24-week, randomized, double-blind, placebo-controlled trial: Up to 75% of subjects with intermediate-to-high risk of MASH progression at baseline who received pemvidutide had their risk reduced to low at Week 24 vs 25% in subjects receiving placebo. Up to 60% of subjects achieved a reduction of both MRI-PDFF and ALT at Week 24 compared with 0% in subjects receiving placebo. Title: Pemvidutide, a glucagon-like peptide 1/glucagon dual receptor agonist, improves metabolic dysfunction-associated steatohepatitis activity and fibrosis in a clinical quantitative systems pharmacology model: A strong correlation was observed between clinically reported and QSP predicted effects ofpemvidutideon weight loss and liver fat content. The QSP model predictedpemvidutide1.8 mg would result in completeresolution of MASH and a 1-point median improvement in fibrosis by Week 24. Taken together, these results suggest that glucagon receptor agonism could have potent effects on MASH fibrosis, over and above GLP-1 monotherapy. Title: Plasma lipidomic profiling of subjects with overweight or obesity following treatment with the glucagon-like peptide 1/glucagon dual receptor agonist pemvidutide: an investigation of lipid signatures associated with metabolic dysfunction-associated steatohepatitis: Subjects treated with pemvidutide had significantly decreased serum lipids from baseline, including glycophospholipids, sphingolipids and other inflammatory lipid subspecies associated with MASH and cardiovascular disease. Pemvidutide treatment was also associated with reduced bile acid dysregulation. Obesity and insulin resistance, two key risk factors for MASH and MASLD, contribute to bile acid dysregulation. Evidence has shown that bile acid dysregulation worsens as MASLD progresses.